First-in-class, dual-mechanism approach to fibrosis
Fibrocor Therapeutics is developing first-in-class therapies that target kidney disease at its roots by blocking fibroblast activation and excessive collagen deposition. The company’s lead focus is Alport Syndrome, a severe condition with no disease-modifying treatments, with the goal of delivering life-changing outcomes for patients who often face early dialysis or transplantation. Using a biomarker-driven approach and human biopsy–derived targets, Fibrocor is advancing a deliberate, translatable clinical strategy and aims to seek accelerated approval for its lead program. Its fibrosis-targeting platform has broad potential across multiple kidney diseases and other organs. Leveraging patient-derived kidney tissue, Fibrocor is also advancing programs in ADPKD and transplant-related fibrosis, identifying precision targets to slow disease progression and preserve long-term organ health.
Initial focus on Alport Syndrome and ADPKD
Fibrocor Therapeutics is initially focused on genetically defined kidney diseases like Alport Syndrome and autosomal polycystic kidney disease (ADPKD), where there is a significant unmet need and no approved disease-modifying therapies.
These conditions are driven by well-understood genetic mutations, enabling increasing diagnosis, precise patient identification and stratification. Fibrocor’s biomarker-driven approach, rooted in human kidney biopsy transcriptomics, allows for accurate target selection, improved trial design, and faster clinical validation.
With an estimated 145,000 diagnosed Alport patients in the U.S. and strong patient advocacy and registry support, the company is well-positioned to recruit and engage patients. Additionally, both indications qualify for orphan drug and fast-track regulatory pathways, and ADPKD has attracted recent pharma interest due to its prevalence and commercial potential.
In due course, Fibrocor plans to expand into broader fibrotic kidney diseases and eventually other organs like the lung and liver.
Lean, experienced team with proven track record
Fibrocor is led by a lean, highly experienced team with a proven track record in fibrosis biology, drug development, and clinical strategy, positioning the company for success. Our leadership includes Piet Wigerinck, former Chief Scientific Officer at Galapagos, who has over 30 years of experience and has been instrumental in developing four approved drugs, as well as holding senior roles at Tibotec and Janssen. Paul Ford brings deep expertise in clinical development, having led biomarker strategy and endpoint design. Fibrocor has secured major collaborations with Galapagos and MSRD/Otsuka, which brought significant investment and scientific validation and demonstrated Fibrocor’s ability to operate to pharma-grade standards.
Fibrocor has previously secured major collaborations with Galapagos and Otsuka, which brought significant investment and contributed to development.
